Stockholders' Deficit (Details)					9 Months Ended
	Aug. 31, 2017	May 04, 2017 USD ($) $ / shares shares	Feb. 10, 2017 USD ($) $ / shares shares	Oct. 11, 2016 USD ($) $ / shares shares	Mar. 31, 2017 USD ($) $ / shares shares	Feb. 16, 2017 USD ($)	Jun. 30, 2016 $ / shares shares
Shares that warrants can purchase				10,000,000
Common stock, par value | $ / shares				$ 3.00	$ 0.01		$ 0.01
Gross proceeds from sale of common stock | $				$ 30,000,000
Net proceeds from sale of common stock | $				$ 28,600,000	$ 43,278,473
Exercise price of warrant | $ / shares				$ 3.75
Preferred stock, shares issued					0		0
Purchase agreement | Seattle Genetics, Inc., (“SGEN”)
Agreement purchase shares of common stock			3,000,000
Shares that warrants can purchase			8,655,804
Common stock, par value | $ / shares			$ 4.90
Gross proceeds from sale of common stock | $			$ 14,700,000
Exercise price of warrant | $ / shares			$ 4.90
Fair value of warrants | $				$ 7,300,000		$ 22,300,000
Warrants term			3 years
Over-Allotment Option
Agreement purchase shares of common stock				10,000,000
Private placement | Purchase agreement | Series A-1 Convertible Preferred Stock | Subsequent Event [Member]
Preferred stock, shares issued		1,000,000
Share price (in dollars per share) | $ / shares		$ 125
Gross proceeds | $		$ 125,000,000
Conversion ratio		23.10536
Conversion of shares		23,105,360
Average stock price | $ / shares		$ 5.41
Dividend percentage	1.00%
Additional dividend percentage	1.00